Currently, IBD treatment mainly depends on anti-inflammatory drugs, immune-modifying agents or immunomodulators, thiopurine agents, and anti-TNF monoclonal antibodies; however, the efficacy of IBD treatment is still unsatisfactory [8]. The gene discussed is TNF; the disease is inflammatory bowel disease.